Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke

Recruiting
18 years - 99 years
All
Phase
N/A
1 Location
Brief description of study
The purpose of this research study is to assess whether lowering of your cholesterol blood level can reduce your risk for major cardiovascular events (for example, heart attack or stroke) when evolocumab is taken in addition to your current medical therapy as directed by your doctor, which may include a medication for the treatment of abnormal cholesterol blood levels called
“statins”
Detailed description of study
You are being asked to take part in this study because your doctor thinks you are at high risk for experiencing a cardiovascular event (like a heart attack or stroke). Elevated cholesterol, in particular low-density lipoprotein cholesterol (LDL-C), can lead to obstructing fatty deposits in blood vessels that can greatly increase your risk of developing cardiovascular disease or experiencing a cardiovascular event.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: stroke,heart,cardiovascular
-
Age: 18 years - 99 years
-
Gender: All
Updated on
19 Feb 2024.
Study ID: 833781